Toxoplasmosis is a zoonotic infection, which is caused by the parasite toxoplasma gondii with a wide range of clinical syndromes in humans. Toxoplasmosis is a potentially life-threatening, serious, and sometimes fatal infection. The Centers for Disease Control and Prevention (CDC) has considered toxoplasmosis to be one of the five neglected parasitic infections. However, a large number of people get infected from toxoplasmosis, but only few patients may experience serious complications. Mostly, the patients suffer from flu-like symptoms until the parasite is controlled by the immune system. The organism can, however, be reactivated in people, including those with compromised immunity. Moreover, active infection may lead to encephalitis (inflammation of the brain), blindness, and mortality.
The route of transmission of Toxoplasma gondii infection are food, contact with animals (cats), water, soil, and others.
The global toxoplasmosis treatment drugs market is estimated to be valued at US$ 2,859.4 million in 2020 and is expected to exhibit a CAGR of 4.9% during the forecast period (2020-2027).
Figure 1. Global Toxoplasmosis Treatment Drugs Market Value (US$ Mn), by Region, 2020
The increasing prevalence of chronic diseases which may lead to toxoplasmosis infection is expected to propel growth of the global toxoplasmosis treatment drugs market
Rising prevalence of cancer and rising chemotherapy procedures may lead to toxoplasmosis infection which is expected to drive the toxoplasmosis treatment drugs market growth. According to Cancer Research U.K., factsheet around 17 million people were diagnosed with cancer in 2018.
According to the same source, the cancer type and new cancer cases in 2018 globally are as follows.
|Rank||Cancer Type||New Cases Diagnosed in 2018|
Rising number of toxoplasmosis cases is the major factor driving the toxoplasmosis treatment drugs market over the forecast period. According to the World Health Organization estimates - Foodborne Disease Burden Epidemiology Reference Group 2007-2015, the global number of Toxoplasma gondii infection are as follows
However, side effects of drugs such as pyrimethamine used in treatment of Toxoplasmosis include hypersensitivity reactions that can occasionally be severe, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and hyperphenylalaninemina which is expected to hamper the market growth. Moreover, the drugs used in toxoplasmosis treatment may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm.
High price of drugs used in the treatment of toxoplasmosis is the major restraining factor hindering the global toxoplasmosis treatment drugs market over the forecast period. For instance, the price of Daraprim is very high – with the list price for one month supply (60 tablets) was nearly US$ 45,000 in 2018 in the U.S.
|Base Year:||2019||Market Size in 2020:||US$ 2,859.4 Mn|
|Historical Data for:||2016 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||4.9%||2027 Value Projection:||US$ 3,996.7 Mn|
Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd., Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.
|Restraints & Challenges:||
Figure 2. Global Toxoplasmosis Treatment Drugs Market Share (%), by Route of Administration, 2020
Global Toxoplasmosis Treatment Drugs Market – Regional Analysis.
On the basis of region, the global toxoplasmosis treatment drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to dominate the global toxoplasmosis treatment drugs market during the forecast period, owing to increasing cancer cases in the region and rising number of chemotherapy procedures. For instance, according to the Cancer Treatment & Survivorship Facts & Figures 2019-2021 report published by the American Cancer Society, Inc., the estimated number of cancer cases in the U.S. was around 16,920,370, as of January 1, 2019.
Moreover, according to the same source, the estimated number of cancer prevalence in the U.S. by cancer type are as follows.
|January 1, 2019||January 1, 2019||January 1, 2030||January 1, 2030|
|Colon & rectum||776,120||994,210||Uterine corpus||807,860||1,023,290|
|Melanoma of the skin||684,470||936,980||Colon & rectum||768,650||965,590|
|Non-Hodgkin lymphoma||400,070||535,870||Non-Hodgkin lymphoma||357,650||480,690|
Global Toxoplasmosis Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic. The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector.
Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global toxoplasmosis treatment drugs market during the forecast period.
Many researchers has started studying to determine the link between COVID-19 and toxoplasmosis. For instance, in May 2020, the scientist from the University of Szczecin, the University of Life Sciences in Pozna? and their colleagues from Hungary, France, and China studied and determined whether there was any link between COVID-19 cases and toxoplasmosis spread by cats and by the protozoan Toxoplasma gondii. The scientist concluded that the interactions between many pathogens can influence the emergence of various diseases and an analysis of toxoplasmosis and coronavirus data from 86 countries showed that most cases of the parasitic disease coincided with a slower spread of COVID-19.
Major players operating in the global toxoplasmosis treatment drugs market are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd., Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.
Toxoplasma gondii is an intracellular parasite, which can cause lifelong infection. The infection lives in the brain and sometimes in the eyes in about 30 percent of all humans. It is caused due to drinking contaminated water, consuming infected undercooked meat, or exposure to these parasites in soil. These parasites usually occur in unborn babies, newborns, children and adults. While most healthy adults who are exposed to the parasite never experience any serious symptoms, but dormant, unrecognized, smoldering infections can emerge years later in immune-compromised patients.
Increasing incidence of cancer is expected to increase the chemotherapy procedures leading to the toxoplasmosis infection, and thereby driving the market growth over the forecast period. According to the World Cancer Research Fund International’s report, in 2018 lung cancer was at first position in the total number of cancer cases worldwide, accounting for 2,093,876 new cases worldwide in 2018. According to the same source, breast cancer accounted second position and the new cases reported was 2,088,849 globally in 2018.
Rising number of chemotherapy procedures can lead to increase in the number of toxoplasmosis infection thereby assisting the market growth. According to the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, in November 2020, stated that nearly 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic annually.
Increasing prevalence of Acquired Immunodeficiency Syndrome (AIDS) caused due to HIV may lead to low immunity and toxoplasmosis infection and, thereby, drive the growth of toxoplasmosis treatment drugs market during the forecast period. For instance, according to the UNAIDS, 2019, around 1.7 million new cases of HIV infection was registered globally in 2018.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients